Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-03-29
2005-03-29
Spector, Lorraine M. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06872699
ABSTRACT:
The present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and truncated Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.
REFERENCES:
patent: 5185438 (1993-02-01), Lemishka
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5766860 (1998-06-01), Terman et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 5869742 (1999-02-01), Köster et al.
patent: WO 9203459 (1992-03-01), None
patent: WO 9214748 (1992-09-01), None
patent: WO 9217486 (1992-10-01), None
patent: WO 9410292 (1994-05-01), None
patent: WO 9521868 (1995-08-01), None
patent: WO 9620403 (1996-07-01), None
Breier et al., “Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation,”Development114:521-532, 1992.
Conn et al., “Purification of a Glycoprotein Vascular Endothelial Cell Mitogen From a Rat Glioma-derived Cell Line,”Proc. Natl. Acad. Sci. USA87:1323-1327, 1990.
Connolly et al., “Human Vascular Permeability Factor, Isolation from U937 Cells,”The Journal of Biological Chemistry, vol. 264, No. 33, p. 20021, (Nov. 25, 1989).
De Vries et al., “Thefms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science255:989-991, 1992.
Ferrara et al., “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,”Biochem. Biophys. Res. Comm.161:851-858, 1989.
Ferrara et al., “The Vascular Endothelial Growth Factor Family of Polypeptides,”J. Cell Biochem.47:211-218, 1991.
Gospodarowicz et al., “Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells,”Proc. Natl. Acad. Sci. USA86:7311-7315, 1989.
Kaskles et al., “A Dominant Negative Mutation Suppresses the Function of Normal Epidermal Growth Factor Receptors by Heterodimerization,”Mol. Cell. Biol.11:1454-1463, 1991.
Klagsburn et al., “Regulators of Angiogenesis”Annu. Rev. Physiol.53:217-39, 1991.
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen,”Science246:1306-1309, 1989.
Li et al., “Monoclonal antibodies to recombinant human vascular endothelial growth factor (rHuVEGF),”Journal of Cellular Biochemistry, vol. Suppl., No. 15F, p. 251, (1991).
Livneh et al., “Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells,”J. Biol. Chem.261(27):12490-12497, 1986.
Maglione et al., “Isolation of Human Placental cDNA Coding For a Protein Related to the Vascular Permeability Factor,”Proc. Natl. Acad. Sci. USA88:9267-9271, 1991.
Matthews et al., “A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primative Hematopoiteic Cells and Exhibiting Close Genetic Linkage toc-kit,”Proc. Natl. Acad. Sci. USA88:9026-9030, 1991.
McCormick, “Human gene therapy: The first round,”Biotechnology3(8):689-693, 1985.
McMahon et al., “Protein kinase inhibitors: structural determinants for target specificity,”Current Opinions in Drug Discovery and Development1(2):131-146, 1998.
Millauer et al., “High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis,”Cell72:835-846, 1993.
Mitchell et al., “Recombinant Expression and Characterization of the 121 Amino Acid Form of Vascular Endothelial Growth Factor (VEGF),”J. Cell. Biochem., Keystone Symposia on Molecular and Cellular Biology, Supplement 15C, Excerpt G207, 1991.
Nicolas et al., “Retroviral Vectors,”Vectors, Chapter 25, pp. 493-494, 1987.
Orkin et al., “Report and Recommendations of the panel to assess the NIH investment in research on gene therapy”, Dec. 7, 1995.
Plate et al., “Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis,”Cancer Research53:5822-5827, 1993.
Prywes et al., “Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization,”EMBO J.5(9):2179-2190, 1986.
Risau et al., “Changes in the Vascular Extracellular Matrix During Embryonic Vasculogenesis and Angiogenesis,”Development Biology125:441-450, 1988.
Sarzani et al., “A Novel Endothelial Tyrosine Kinase cDNA Homologous To Platelet-Derived Growth Factor Receptor cDNA”Biochem. Biophys. Res. Comm.186:706-714, 1992.
Spivak-Kroizman et al., “Heterodimerization of c-erbB2 With Different Epidermal Growth Factor Receptor Mutants Elicit Stimulatory or Inhibitory Responses,”J. Biol. Chem.267:8056-8063, 1992.
Strawn et al., “Flk-1 as a Target for Tumor Growth Inhibition,”Cancer Research56:3540-3545, 1996.
Tartaglia et al., J. Biol. Chem. 267(7), 4304-4307, Mar. 5, 1992.
Terman et al., “Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase,”Oncogene6:1677-1683, 1991.
Terman et al., “Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor,”Biochem. Biophys. Res. Comm.187:1579-1586, 1992.
Traxler, “Tyrosine kinase inhibitors in cancer treatment (Part II),”Exp. Opin. Ther. Patents8(12):1599-1625, 1998.
Ueno et al., J. Biol. Chem. 267(3):1470-1476, Jan. 25, 1992.
Ueno et al., Science 252:844-848, May 10, 1991.
Ullrich et al., “Signal transduction by receptors with tyrosine kinase activity”,Cell61:203-212, 1990.
Gazit Aviv
Levitzki Alex
Millauer Birgit
Risau Werner
Ullrich Axel
Burrous Beth A.
Foley & Lardner LLP
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.
Spector Lorraine M.
LandOfFree
Truncated Flk-1 receptor protein, methods of use and a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated Flk-1 receptor protein, methods of use and a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated Flk-1 receptor protein, methods of use and a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373558